FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2118859574> ?p ?o ?g. }

• W2118859574 endingPage "1510" @default.
• W2118859574 startingPage "1497" @default.
• W2118859574 abstract "As a result of the reported efficacy of oral Bisphosphonates in reducing fractures, increasing bone mineral density (BMD), and reducing bone turnover, these agents are the recommended first line of treatment of postmenopausal osteoporosis. However, in clinical practice, patients might not be diagnosed or prescribed appropriate treatment. Even when bisphosphonates are prescribed, their therapeutic benefit may be compromised by poor treatment compliance and/or failure to persist with the treatment prescribed. New drugs or treatment regimens that reduce the risk for osteoporotic fractures and make the treatment of osteoporosis more convenient and suitable for patients are needed.The aims of the present review were to discuss the efficacy of monthly ibandronate in the treatment of postmenopausal osteoporosis and to determine treatment adherence with this drug.A search of MEDLINE (key terms: ibandronate and ibandronic acid; publication dates: 1996-December 2008) was used to identify studies of the efficacy and adherence of ibandronate in the treatment of postmenopausal osteoporosis. Additional searches were conducted to identify publications pertinent to compliance using the terms bisphosphonate and compliance.A total of 15 articles were included in the present review. An analysis of data from 2 US data-bases reported that once-monthly ibandronate was associated with significantly improved treatment persistence relative to weekly bisphosphonates at 1 year. In BONE (Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe), the risk for new vertebral fractures was reduced by 62% with oral ibandronate 2.5 mg/d versus placebo (P < 0.001) at 3 years. In the 2-year MOBILE (Monthly Oral Ibandronate in Ladies) study, oral ibandronate 150 mg once monthly was associated with significantly increased lumbar spine BMD (P < 0.001), and bone turnover markers were numerically decreased compared with the daily regimen. A meta-analysis reported a 38% lower risk for nonvertebral fractures with combined high doses of ibandronate (including oral iban-dronate 150 mg monthly and ibandronate 3 mg IV every 3 months) compared with oral ibandronate 2.5 mg/d (change in annual cumulative exposure, from > or =10.8 to 5.5 mg).Based on the findings from the studies included in the present review, treatment with oral ibandronate 150 mg once monthly was reported to be at least as effective as the daily regimen and was associated with increased adherence. Monthly iban-dronate might provide an option for the treatment of postmenopausal osteoporosis." @default.
• W2118859574 created "2016-06-24" @default.
• W2118859574 creator A5013752581 @default.
• W2118859574 creator A5026470430 @default.
• W2118859574 creator A5038627121 @default.
• W2118859574 creator A5045315263 @default.
• W2118859574 date "2009-07-01" @default.
• W2118859574 modified "2023-09-24" @default.
• W2118859574 title "Once-monthly oral ibandronate in postmenopausal osteoporosis: Translation and updated review" @default.
• W2118859574 cites W123345555 @default.
• W2118859574 cites W123989875 @default.
• W2118859574 cites W1492812147 @default.
• W2118859574 cites W150791944 @default.
• W2118859574 cites W1883130365 @default.
• W2118859574 cites W190001218 @default.
• W2118859574 cites W1917904146 @default.
• W2118859574 cites W1964315400 @default.
• W2118859574 cites W1966722256 @default.
• W2118859574 cites W1968717221 @default.
• W2118859574 cites W1971046106 @default.
• W2118859574 cites W1973356978 @default.
• W2118859574 cites W1974201106 @default.
• W2118859574 cites W1974729922 @default.
• W2118859574 cites W1978138475 @default.
• W2118859574 cites W1985160737 @default.
• W2118859574 cites W1987169166 @default.
• W2118859574 cites W1988202089 @default.
• W2118859574 cites W1989637027 @default.
• W2118859574 cites W1990173735 @default.
• W2118859574 cites W1993701679 @default.
• W2118859574 cites W1998033364 @default.
• W2118859574 cites W2005298224 @default.
• W2118859574 cites W2011470894 @default.
• W2118859574 cites W2012291531 @default.
• W2118859574 cites W2024412436 @default.
• W2118859574 cites W2026123506 @default.
• W2118859574 cites W2031014341 @default.
• W2118859574 cites W2052724914 @default.
• W2118859574 cites W2065916720 @default.
• W2118859574 cites W2070531118 @default.
• W2118859574 cites W2082229075 @default.
• W2118859574 cites W2085517891 @default.
• W2118859574 cites W2089272876 @default.
• W2118859574 cites W2091930575 @default.
• W2118859574 cites W2099054178 @default.
• W2118859574 cites W2099606865 @default.
• W2118859574 cites W2102123887 @default.
• W2118859574 cites W2104922575 @default.
• W2118859574 cites W2107544704 @default.
• W2118859574 cites W2108526974 @default.
• W2118859574 cites W2109465803 @default.
• W2118859574 cites W2110828193 @default.
• W2118859574 cites W2124503314 @default.
• W2118859574 cites W2124527463 @default.
• W2118859574 cites W2128778774 @default.
• W2118859574 cites W2134664830 @default.
• W2118859574 cites W2147255557 @default.
• W2118859574 cites W2150410663 @default.
• W2118859574 cites W2156015681 @default.
• W2118859574 cites W2156032366 @default.
• W2118859574 cites W2161837912 @default.
• W2118859574 cites W2162255898 @default.
• W2118859574 cites W2288165237 @default.
• W2118859574 cites W2321227665 @default.
• W2118859574 cites W2330096705 @default.
• W2118859574 cites W2416267195 @default.
• W2118859574 cites W285003579 @default.
• W2118859574 cites W2952011418 @default.
• W2118859574 cites W50329224 @default.
• W2118859574 doi "https://doi.org/10.1016/j.clinthera.2009.07.018" @default.
• W2118859574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19695399" @default.
• W2118859574 hasPublicationYear "2009" @default.
• W2118859574 type Work @default.
• W2118859574 sameAs 2118859574 @default.
• W2118859574 citedByCount "13" @default.
• W2118859574 countsByYear W21188595742012 @default.
• W2118859574 countsByYear W21188595742013 @default.
• W2118859574 countsByYear W21188595742014 @default.
• W2118859574 countsByYear W21188595742017 @default.
• W2118859574 crossrefType "journal-article" @default.
• W2118859574 hasAuthorship W2118859574A5013752581 @default.
• W2118859574 hasAuthorship W2118859574A5026470430 @default.
• W2118859574 hasAuthorship W2118859574A5038627121 @default.
• W2118859574 hasAuthorship W2118859574A5045315263 @default.
• W2118859574 hasConcept C126322002 @default.
• W2118859574 hasConcept C142724271 @default.
• W2118859574 hasConcept C204787440 @default.
• W2118859574 hasConcept C27081682 @default.
• W2118859574 hasConcept C2776541429 @default.
• W2118859574 hasConcept C2776886416 @default.
• W2118859574 hasConcept C2777251235 @default.
• W2118859574 hasConcept C3018571302 @default.
• W2118859574 hasConcept C535046627 @default.
• W2118859574 hasConcept C71924100 @default.
• W2118859574 hasConceptScore W2118859574C126322002 @default.
• W2118859574 hasConceptScore W2118859574C142724271 @default.
• W2118859574 hasConceptScore W2118859574C204787440 @default.
• W2118859574 hasConceptScore W2118859574C27081682 @default.

• next